Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06448793

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-small Cell Lung Cancer (NSCLC) Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Evidera

London, United Kingdom

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients

  • Aged ≥18 years at the time of enrollment in the study
  • Resident of the US, Germany, or Japan
  • Able to read, speak, and understand English, German or Japanese
  • Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)

Physicians

  • Resident of the US, Germany, or Japan
  • Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology
  • Treated at least three new patients with resectable NSCLC in the past year

Exclusion criteria

Patients

  • Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
  • Being diagnosed with another malignancy alongside NSCLC
  • Not willing to be audio-recorded during the interview

Physicians

  • Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
  • Not willing to be audio-recorded during the interview

Treatment and study plan

Approved Non-small Cell Lung Cancer (NSCLC) therapies

Drug

As prescribed by treating physician

Primary outcomes

  1. Responses to qualitative interview questions

    Time frame: Day 1

    Interview questions designed to gather insights into diagnosis, symptoms, current treatments, perspectives on treatment features and test for mock preferences tasks. The interview will take 15 minutes to complete.

  2. Patient sociodemographic

    Time frame: Day 1

  3. Patient clinical characteristics

    Time frame: Day 1

Study contacts

Contact information is provided by the study sponsor or research team.

BMS Study Connect Contact Center www.BMSStudyConnect.com

CONTACT

[email protected]

855-907-3286

First line of the email MUST contain NCT # and Site #.

CONTACT

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jun 7, 2024
Registry last updated
Dec 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.